RU2106143C1 - Вещество для преодоления мультилекарственной устойчивости - Google Patents
Вещество для преодоления мультилекарственной устойчивости Download PDFInfo
- Publication number
- RU2106143C1 RU2106143C1 RU93056139A RU93056139A RU2106143C1 RU 2106143 C1 RU2106143 C1 RU 2106143C1 RU 93056139 A RU93056139 A RU 93056139A RU 93056139 A RU93056139 A RU 93056139A RU 2106143 C1 RU2106143 C1 RU 2106143C1
- Authority
- RU
- Russia
- Prior art keywords
- substance
- formula
- phthalazinone derivative
- cells
- μmol
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims description 12
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 claims description 8
- 230000003287 optical effect Effects 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 2
- 230000036457 multidrug resistance Effects 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- -1 C 1 - C 3 -alkyl Chemical group 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 20
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 11
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 11
- 229960000975 daunorubicin Drugs 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 6
- 229960004574 azelastine Drugs 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000000737 periodic effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical class C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 4
- 230000003288 anthiarrhythmic effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000000824 cytostatic agent Substances 0.000 description 3
- 230000037024 effective refractory period Effects 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000005241 right ventricle Anatomy 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 2
- 108010036949 Cyclosporine Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 210000005246 left atrium Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960001156 mitoxantrone Drugs 0.000 description 2
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 210000003540 papillary muscle Anatomy 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 0 *C(C=C(*)c1ccccc11)NC1=O Chemical compound *C(C=C(*)c1ccccc11)NC1=O 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- 241000896693 Disa Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000005929 chemotherapeutic response Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001506 fluorescence spectroscopy Methods 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP4233113.7 | 1992-10-02 | ||
| DE4233113 | 1992-10-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU93056139A RU93056139A (ru) | 1996-09-10 |
| RU2106143C1 true RU2106143C1 (ru) | 1998-03-10 |
Family
ID=6469448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU93056139A RU2106143C1 (ru) | 1992-10-02 | 1993-10-01 | Вещество для преодоления мультилекарственной устойчивости |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5556856A (enExample) |
| EP (1) | EP0590551B1 (enExample) |
| JP (1) | JP3623975B2 (enExample) |
| CN (1) | CN1088435A (enExample) |
| AT (1) | ATE144708T1 (enExample) |
| AU (1) | AU666773B2 (enExample) |
| CA (1) | CA2107548A1 (enExample) |
| CZ (1) | CZ199593A3 (enExample) |
| DE (1) | DE59304351D1 (enExample) |
| DK (1) | DK0590551T3 (enExample) |
| ES (1) | ES2096168T3 (enExample) |
| GR (1) | GR3022070T3 (enExample) |
| HU (1) | HUT65353A (enExample) |
| MX (1) | MX9306120A (enExample) |
| RU (1) | RU2106143C1 (enExample) |
| SK (1) | SK104493A3 (enExample) |
| UA (1) | UA26953C2 (enExample) |
| ZA (1) | ZA937315B (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162616A (en) * | 1997-04-16 | 2000-12-19 | Millennium Pharmaceuticals, Inc. | Multidrug resistance-associated polypeptide |
| US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| AU2002363523A1 (en) * | 2001-11-07 | 2003-05-19 | Pharmacia Corporation | Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells |
| JP4500161B2 (ja) | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | フタラジノン誘導体 |
| GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7294701B2 (en) * | 2003-04-02 | 2007-11-13 | Technion Research & Development Foundation Ltd. | Antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same |
| GB0419072D0 (en) | 2004-08-26 | 2004-09-29 | Kudos Pharm Ltd | Phthalazinone derivatives |
| GB0428111D0 (en) * | 2004-12-22 | 2005-01-26 | Kudos Pharm Ltd | Pthalazinone derivatives |
| GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
| TW200811116A (en) * | 2006-04-20 | 2008-03-01 | Glaxo Group Ltd | Compounds |
| EP2041110A1 (en) * | 2006-06-15 | 2009-04-01 | Kudos Pharmaceuticals Limited | 2 -oxyheteroarylamide derivatives as parp inhibitors |
| EP2035380A2 (en) * | 2006-06-15 | 2009-03-18 | Kudos Pharmaceuticals Limited | Parp inhibitors |
| EP2041087A1 (en) * | 2006-06-15 | 2009-04-01 | Kudos Pharmaceuticals Limited | 2 -oxybenzamide derivatives as parp inhibitors |
| UY30639A1 (es) | 2006-10-17 | 2008-05-31 | Kudos Pharm Ltd | Derivados sustituidos de 2h-ftalazin-1-ona, sus formas cristalinas, proceso de preparacion y aplicaciones |
| DE602007005167D1 (de) * | 2006-12-20 | 2010-04-15 | Glaxo Group Ltd | 4-benzyl-1(2h)-phthalazinone als h1-rezeptor-antagonisten |
| US20080280910A1 (en) * | 2007-03-22 | 2008-11-13 | Keith Allan Menear | Phthalazinone derivatives |
| TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
| US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
| AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
| ATE525370T1 (de) * | 2007-10-11 | 2011-10-15 | Glaxo Group Ltd | Phthalazin- und pyridoä3,4- düpyridazinverbindungen als h1-rezeptor- antagonisten |
| CN101821242B (zh) | 2007-10-17 | 2013-07-24 | 库多斯药物有限公司 | 4-[3-(4-环丙烷羰基-哌嗪-1-羰基)-4-氟-苄基]-2h-酞嗪-1-酮 |
| AR070221A1 (es) | 2008-01-23 | 2010-03-25 | Astrazeneca Ab | Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas. |
| HUE030800T2 (en) | 2008-10-07 | 2017-05-29 | Astrazeneca Uk Ltd | Pharmaceutical Form No. 514 |
| TW201114756A (en) * | 2009-07-15 | 2011-05-01 | Astrazeneca Ab | Phthalazinone compound |
| US8937178B2 (en) | 2013-03-13 | 2015-01-20 | Flatley Discovery Lab | Phthalazinone compounds and methods for the treatment of cystic fibrosis |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3677322D1 (de) * | 1985-11-11 | 1991-03-07 | Asta Pharma Ag | 4-benzyl-1-(2h)-phthalazinon-derivate. |
| JPH0667844B2 (ja) * | 1987-03-06 | 1994-08-31 | エーザイ株式会社 | 虚血性心疾患の治療・予防剤 |
| US5110814A (en) * | 1989-01-11 | 1992-05-05 | Asta Pharma Ag | Azelastine and its salts used to combat psoriasis |
-
1993
- 1993-09-24 CZ CZ931995A patent/CZ199593A3/cs unknown
- 1993-09-25 EP EP93115512A patent/EP0590551B1/de not_active Expired - Lifetime
- 1993-09-25 ES ES93115512T patent/ES2096168T3/es not_active Expired - Lifetime
- 1993-09-25 DE DE59304351T patent/DE59304351D1/de not_active Expired - Lifetime
- 1993-09-25 AT AT93115512T patent/ATE144708T1/de not_active IP Right Cessation
- 1993-09-25 DK DK93115512.1T patent/DK0590551T3/da active
- 1993-09-29 CN CN93118175A patent/CN1088435A/zh active Pending
- 1993-09-30 SK SK1044-93A patent/SK104493A3/sk unknown
- 1993-09-30 UA UA93002239A patent/UA26953C2/uk unknown
- 1993-10-01 AU AU48769/93A patent/AU666773B2/en not_active Ceased
- 1993-10-01 JP JP24683493A patent/JP3623975B2/ja not_active Expired - Fee Related
- 1993-10-01 RU RU93056139A patent/RU2106143C1/ru active
- 1993-10-01 HU HU9302784A patent/HUT65353A/hu unknown
- 1993-10-01 ZA ZA937315A patent/ZA937315B/xx unknown
- 1993-10-01 CA CA002107548A patent/CA2107548A1/en not_active Abandoned
- 1993-10-01 MX MX9306120A patent/MX9306120A/es unknown
-
1995
- 1995-04-04 US US08/416,467 patent/US5556856A/en not_active Expired - Fee Related
-
1996
- 1996-12-18 GR GR960403515T patent/GR3022070T3/el unknown
Non-Patent Citations (1)
| Title |
|---|
| Cancer Chemothir. Pharmacol, 1992, 29, 413-429. * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0590551B1 (de) | 1996-10-30 |
| UA26953C2 (uk) | 1999-12-29 |
| HU9302784D0 (en) | 1993-12-28 |
| AU4876993A (en) | 1994-04-14 |
| MX9306120A (es) | 1994-04-29 |
| ES2096168T3 (es) | 1997-03-01 |
| US5556856A (en) | 1996-09-17 |
| ATE144708T1 (de) | 1996-11-15 |
| CZ199593A3 (en) | 1994-04-13 |
| DK0590551T3 (da) | 1997-04-21 |
| JP3623975B2 (ja) | 2005-02-23 |
| AU666773B2 (en) | 1996-02-22 |
| SK104493A3 (en) | 1994-08-10 |
| CA2107548A1 (en) | 1994-04-03 |
| GR3022070T3 (en) | 1997-03-31 |
| EP0590551A3 (enExample) | 1994-08-31 |
| DE59304351D1 (de) | 1996-12-05 |
| JPH06312928A (ja) | 1994-11-08 |
| CN1088435A (zh) | 1994-06-29 |
| EP0590551A2 (de) | 1994-04-06 |
| ZA937315B (en) | 1994-04-22 |
| HUT65353A (en) | 1994-05-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2106143C1 (ru) | Вещество для преодоления мультилекарственной устойчивости | |
| Sakai et al. | Specific angiotensin II receptors in organ-cultured canine supra-optic nucleus cells | |
| Langer et al. | Localization of contractile-dependent Ca: comparison of Mn and verapamil in cardiac and skeletal muslce | |
| Gray | Cellular radiobiology | |
| EP3906240A1 (en) | Compositions and methods for modulating hair growth | |
| WO2024182469A1 (en) | Myosin inhibitors for use in the treatment of hypertrophic cardiomyopathy | |
| SU1545941A3 (ru) | Способ получени оксотиазолидиновых соединений | |
| Parker et al. | Contractile dysfunction of atrial myocardium from endotoxin-shocked guinea pigs | |
| Lieberman | Effects of cell density and low K on action potentials of cultured chick heart cells | |
| US20070105147A1 (en) | Rapid method for screening compounds for in vivo activity | |
| KR100545930B1 (ko) | 첼리도닌 또는 그 유도체를 포함하는 약제학적 조성물 | |
| QUINN et al. | Species variation in arterial-myocardial sensitivity to verapamil | |
| Kaneko | Alteration of Acetylcholinesterase in the Cochlea | |
| Hagiwara et al. | Dose-dependent renal tubular toxicity of harman and norharman in male F344 rats | |
| Edery et al. | Target sites for anticholinesterases on the ventral surface of the medulla oblongata: hypotension elicited by organophosphorus agents | |
| Park et al. | Effects of flunarizine on impulse initiation in canine Purkinje fibers | |
| Wibe et al. | Cell-cycle inhibitory effects of the mitotic inhibitor NY 3170 on human cells in vitro | |
| Bailey | Orotic acid prevents changes in cardiac sarcolemmal glycoproteins and contractility associated with muscular dystrophy in hamsters | |
| Jaffe | Eggs are activated by a calcium explosion: Carcinogenesis may involve calcium adaptation and habituation | |
| Lee et al. | Developmental aspects of the myocardial staircase phenomenon: Effects of insulin | |
| EA042750B1 (ru) | Композиции и способы модуляции роста волос | |
| CA1339503C (en) | Method and composition for ameliorating the adverse effects of aging | |
| DINCER et al. | The effects of chronic L-NAME and L-arginine administration on β-adrenergic responsiveness of STZ-diabetic rat atria | |
| US5723487A (en) | Preparation of a product for treatment of colagen-related disorders | |
| EP4337199A1 (en) | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |